Advertisement
News
Advertisement

RXi plans IND for anti-scarring treatment

Fri, 12/17/2010 - 10:33am
Mass High Tech: The Journal of New England Technology

RXi Pharmaceuticals Corp. of Worcester is preparing to bring its first RNAi product into development, with the filing of an investigational new drug (IND) application for its therapeutic candidate in reducing surgical scarring.

RXI-109, its self-delivering RNAi compound, is described by RXi as helping to reduce dermal scarring because of its ability to silence a gene target known to modulate fibrosis. According to an RXi press release, no drugs have been approved yet for dermal anti-scarring.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading